Clinical Trial Detail

NCT ID NCT02273752
Title Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Emory University
Indications

Her2-receptor negative breast cancer

renal cell carcinoma

pancreatic endocrine carcinoma

Therapies

Everolimus

Age Groups: adult

Additional content available in CKB BOOST